
Nano-X Imaging (NNOX) Stock Forecast & Price Target
Nano-X Imaging (NNOX) Analyst Ratings
Bulls say
Nano X Imaging Ltd reported a quarterly revenue increase to $3.4 million, reflecting improved margins and greater utilization of its teleradiology services. The company's strategic partnership with Imperial Imaging Technology aims to enhance the deployment of its Nanox.ARC system across six Southeastern states, aligning with its goal to improve access to point-of-care imaging. Additionally, the recent FDA 510(k) clearance for the TAP2D cloud-enabled image enhancement capability is poised to enhance the Nanox.ARC's diagnostic capabilities, further solidifying management's confidence in achieving their 2026 revenue guidance of $35 million and supporting overall business expansion.
Bears say
Nano X Imaging Ltd has reported a significant decrease in cash reserves, totaling $55.5 million, down from $83.2 million at the year's end, indicating a troubling cash burn of $30.4 million and usage of the at-the-market (ATM) financing. The company has maintained a GAAP gross loss of $2.9 million and a stable net loss of $13.7 million, suggesting that despite investments in system deployments and AI infrastructure, profitability remains elusive. Additionally, the prolonged development and regulatory timelines, coupled with increased investment requirements beyond original expectations, contribute to a negative outlook for the company's future financial performance.
This aggregate rating is based on analysts' research of Nano-X Imaging and is not a guaranteed prediction by Public.com or investment advice.
Nano-X Imaging (NNOX) Analyst Forecast & Price Prediction
Start investing in Nano-X Imaging (NNOX)
Order type
Buy in
Order amount
Est. shares
0 shares